TRDA Entrada Therapeutics Inc
Price (delayed)
$8.8
Market cap
$330.83M
P/E Ratio
5
Dividend/share
N/A
EPS
$1.76
Enterprise value
$284.88M
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody,
Highlights
The equity has soared by 77% YoY
TRDA's quick ratio has surged by 68% since the previous quarter
The gross profit has surged by 63% year-on-year but it has declined by 2.1% since the previous quarter
Entrada Therapeutics's revenue has soared by 63% YoY but it has decreased by 2.1% from the previous quarter
Key stats
What are the main financial stats of TRDA
Market
Valuations
Earnings
Shares outstanding
37.59M
Market cap
$330.83M
Enterprise value
$284.88M
Price to earnings (P/E)
5
Price to book (P/B)
0.77
Price to sales (P/S)
1.56
EV/EBIT
4.28
EV/EBITDA
4.05
EV/Sales
1.35
Revenue
$210.78M
Gross profit
$210.78M
Operating income
$47.01M
Net income
$65.63M
EBIT
$66.49M
EBITDA
$70.26M
Free cash flow
-$44.72M
Per share
Balance sheet
Liquidity
EPS
$1.76
EPS diluted
$1.68
Free cash flow per share
-$1.2
Book value per share
$11.46
Revenue per share
$5.65
TBVPS
$14.11
Total assets
$526.32M
Total liabilities
$97.64M
Debt
$59.21M
Equity
$428.68M
Working capital
$400.56M
Debt to equity
0.14
Current ratio
11.15
Quick ratio
10.83
Net debt/EBITDA
-0.65
Margins
Efficiency
Dividend
EBITDA margin
33.3%
Gross margin
100%
Net margin
31.1%
Operating margin
22.3%
Return on assets
12.1%
Return on equity
16.9%
Return on invested capital
16.6%
Return on capital employed
13.7%
Return on sales
31.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TRDA stock price
How has the Entrada Therapeutics stock price performed over time
Intraday
0.46%
1 week
-11.11%
1 month
-26.3%
1 year
-36.6%
YTD
-49.1%
QTD
-2.65%
Financial performance
How have Entrada Therapeutics's revenue and profit performed over time
Revenue
$210.78M
Gross profit
$210.78M
Operating income
$47.01M
Net income
$65.63M
Gross margin
100%
Net margin
31.1%
The gross profit has surged by 63% year-on-year but it has declined by 2.1% since the previous quarter
Entrada Therapeutics's revenue has soared by 63% YoY but it has decreased by 2.1% from the previous quarter
TRDA's net margin is up by 22% from the previous quarter
The operating income is down by 19% since the previous quarter
Growth
What is Entrada Therapeutics's growth rate over time
Valuation
What is Entrada Therapeutics stock price valuation
P/E
5
P/B
0.77
P/S
1.56
EV/EBIT
4.28
EV/EBITDA
4.05
EV/Sales
1.35
TRDA's P/E is 55% less than its last 4 quarters average of 11.1
TRDA's EPS is up by 5% from the previous quarter
The equity has soared by 77% YoY
TRDA's price to book (P/B) is 49% lower than its last 4 quarters average of 1.5
Entrada Therapeutics's revenue has soared by 63% YoY but it has decreased by 2.1% from the previous quarter
The stock's P/S is 45% less than its last 4 quarters average of 2.8
Efficiency
How efficient is Entrada Therapeutics business performance
The ROIC has declined by 20% since the previous quarter
Entrada Therapeutics's return on assets has increased by 16% QoQ
TRDA's ROS is down by 11% from the previous quarter
Entrada Therapeutics's return on equity has increased by 5% QoQ
Dividends
What is TRDA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TRDA.
Financial health
How did Entrada Therapeutics financials performed over time
Entrada Therapeutics's current ratio has surged by 69% QoQ
TRDA's quick ratio has surged by 68% since the previous quarter
TRDA's debt is 86% less than its equity
The equity has soared by 77% YoY
Entrada Therapeutics's debt to equity has plunged by 50% YoY and by 7% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.